急性早幼粒细胞白血病小鼠动物模型建立的研究现状

doi:10.11904/j.issn.1002-3070.2017.05.013

Abstract

Abstract: Acute promyelocytic leukemia(APL)is a class of malignant disease of hematopoietic tissue.Animal models are important tools for exploring human-related diseases.Many studies have beer shown that APL mouse models can be established by transgenic,retroviral-mediated and leukemia cell transplantation.These models established by these three methods can be re-transplanted.The establishment of these models lays the foundation for understanding the pathogenesis and efficacy of APL.In order to determine whether the model is successfully established,these methods can be used for blood tests,blood smear and bone marrow smear,immunology,molecular biology and pathology related to complete the examination.Successful establishment of APL animal model can provide important experimental basis and theoretical basis for the study,development and evaluation of drug efficacy in APL,which will help people to understand human APL further.

Key words: Acute promyelocytic leukemia, Animal model, FVB/NJ mice

CLC Number:

R733.7

WANG Yitong, XU Wen. Current status of the establishment of acute promyelocytic leukemia in mouse models[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 454-457.

References

1 Cicconi L,Lo-Coco F.Current management of newly diagnosed acute promyelocytic leukemia[J].Ann Oncol,2016,27(8):1474-1481.
2 Testa U,Lo-Coco F.Prognostic factors in acute promyelocytic leukemia:strategies to define high-risk patients[J].Ann Hematol,2016,95(5):673-680.
3 饶毅,黎润红,张大庆.化毒为药:三氧化二砷对急性早幼粒白血病治疗作用的发现[J].中国科学生命科学,2013,43(8):700-707.
4 Iland HJ,Bradstock K,Supple SG,et al.All-trans-retinoic acid,idarubicin,and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia(APML4)[J].Blood,2012,120(8):1570-1580.
5 Lou Y,Qian W,Meng H,et al.High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia[J].Leuk Res,2013,37(1):37-42.
6 高晓慧,田新,杨春会,等.急性早幼粒白血病的治疗进展[J].实用临床医学,2015,16(6):98-100.
7 孟秀琴,成国祥,曹文俊,等.PML-RARα转基因小鼠发生急性早幼粒细胞白血病[J].中国实验血液学杂志,2000,8(2):104-109.
8 董颖,陈娟丽,陈思宇,等.hCG/RARα/PIZF转基因小鼠发生髓系增殖性疾病[J].中华血液学杂志,2004,25(12):745-747.
9 王骏,王珊珊,杨德宣,等.人急性早幼粒细胞白血病小鼠模型的建立[J].中国临床药理学与治疗学,2013,18(8):858-864.
10 Rego EM,Ruggero D,Tribioli C,et al.Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR,PLZF/RAR or NPM/RAR[J].Oncogene,2006,25(13):1974-1979.
11 施琳,王月英,陈赛娟.逆转录病毒介导的髓系白血病小鼠模型研究的最新进展[J].中国实验血液学杂志,2011,19(4):1058-1063.
12 Wartman LD,Welch JS,Uy GL,et al.Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice[J].PLoS One,2012,7(10):e46529.
13 陈娟丽,董颖,陈思宇,等.PLZF-RARα/RARα-PLZF双阳性转基因小鼠发生白血病模型研究[J].中国实验血液学杂志,2005,13(6):924-931.
14 Kogan SC.Moue models of acute promyelocytic leukemia[J].Curr Top Microbiol Immunol,2007,313:3-29.
15 Nasr R,Lallemand-Breitenbach V,Zhu J,et al.Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure[J].Clin Cancer Res,2009,15(20):6321-6326.
16 杨文华,于文俊,史哲新,等.人白血病-NOD/SCID小鼠髓外浸润模型的建立[J].现代肿瘤医学,2009,17(4):605-608.
17 Liu YF,Zhang M,Cheng XY,et al.Establishment of the human acute promyelocytic leukemia pathological model in the SCID mice by using NB4 cell line[J].J Exp Hematol,2015,23(1):50-54.
18 Li H,Wang R,Li XX,et al.Carnosic acid-combined arsenic trioxide anti-leukaemia cells in the establishment of NB4/SCID mouse model[J].Basic Clin Pharmacol Toxicol,2016,119(3):259-266.
19 Pollock JL,Lane AA,Schrimpf K,et al.Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms[J].Haematologica,2005,90(8):1042-1049.
20 黄檬檬,诸江,胡烔.急性早幼粒细胞白血病小鼠模型中造血增殖、定位和迁移特点的研究[J].诊断学理论与实践杂志,2013,12(3):326-329.
21 付林林,陈日玲,赵桂娟,等.SCID小鼠-人白血病模型中关键因素的分析[J].中国实验血液学杂志,2015,23(1):55-60.
22 Rego EM,He LZ,Warrell RPJ,et al.Retinoic acid(RA)and As₂O₃ treatment in transgenic models of acute promyelocytic leukemia(APL)unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins[J].Proc Natl Acad Sci U S A,2000,97(18):10173-10178.
23 桑奕雯.外周血细胞计数与形态学检查对常见白血病诊断的重要性[J].国际检验医学杂志,2014,35(21):2934-2938.
24 杨红,刘建兴,周泽平,等.应用SCID和NOD/SCID小鼠构建急性髓系白血病模型成瘤率的比较[J].中国实验血液学杂志,2015,23(2):328-334.
25 Ahn S,Park JS,Jeong SH,et al.Current routine practice and clinico-pathological characteristics associated with acute promyelocytic leukemia in Korea[J].Blood Res,2013,48(1):31-34.
26 Lo-Coco F,Avvisati G,Vignetti M,et al.Retinoic acid and arsenic trioxide for acute promyelocytic leukemia[J].N Engl J Med,2013,369(2):111-121.
27 Oviedo A,Yañez R,Colmenero I,et al.Reduced efficacy of mesenchymal stromal cells in preventing graft-versus-host disease in an in vivo model of haploidentical bone marrow transplant with leukemia[J].Cell Transplant,2013,22(8):1381-1394.

[1]	LI Yipeng, ZHANG Xinyu, LV Hanning, SUN Lichun. Research progression of MLLT6 in leukemia [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 135-139.
[2]	DU Yaru, ZHAO Yanhong, ZHOU Jin. The research progress in transfusion-related iron overload in hematological malignancies [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 78-82.
[3]	SUN Guoqiang, SUN Lichun. Treatment progress of chemotherapy induced thrombocytopenia [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 184-188.
[4]	ZHOU Maiyu,ZHANG Zhuo,ZHOU Jin. The experimental progress on arsenic trioxide for non-APL and solid tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 144-148.
[5]	GUO Jingjie , XU Wen. The current research of arsenic trioxide in the treatment of acute promyelocytic leukemia [J]. PRACTICAL ONCOLOGY JOURNAL, 0, (): 167-171.

Current status of the establishment of acute promyelocytic leukemia in mouse models

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

Comments